quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 11, 2026

UPS navigates Amazon draw down in hard pivot to premium services

View original at finance.yahoo.com
“Domestic revenue is projected to increase by low-single digits from last year, with an operating margin of about 8%.”
Verbatim excerpt from the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Analysts are giving UPS solid marks in executing largest network consolidation in its history without noticeable impact on service levels

    60% confidence
  • Primary cause of lower volumes was deliberate decision to shed 50% of Amazon volume because it didn't make money

    60% confidence
  • FedEx is prioritizing high-value B2B segments and premium e-commerce over last-mile delivery

    60% confidence
  • UPS strategic focus shifting to less e-commerce, more small-and-medium business, more B2B, more healthcare

    60% confidence
  • UPS expects soft revenue environment and operational adjustment costs to weigh on profits in first half of year, with improvement in second half as efficiency measures flow to bottom line

    60% confidence
  • UPS cost-reduction program is positioning company for profitable growth, creating more agile and profitable network to grow with right type of volume

    60% confidence

Data points we hold from this source

United Parcel Service · amazon throughput reduction2000000 pieces_per_day
United Parcel Service · revenue reduction amazon5 USD
United Parcel Service · amazon volume reduction50 percent
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
UPS navigates Amazon draw down in hard pivot to premium services — Source | Via News | pt.VIA.NEWS